CONTRACEPTION Journal
Overview
publication venue for
- The efficacy, safety, and tolerability of an estrogen-free oral contraceptive drospirenone 4 mg (24/4-day regimen) in obese users. 128. 2023
- Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials. 116:44-50. 2022
- Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimens. 112:54-60. 2022
- Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. 104:222-228. 2021
- Segesterone acetate serum levels with a regression model of continuous use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system. 104:229-234. 2021
- Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate. 102:168-173. 2020
- Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate. 102:168-173. 2020
- A phase I randomized safety study of a single-size silicone rubber diaphragm used with or without a lactic-acid-containing diaphragm gel. 100:430-437. 2019
- Acceptability of the Woman's Condom in a phase III multicenter open-label study. 99:357-362. 2019
- Comparison of self-reported female condom failure and biomarker-confirmed semen exposure. 100:406-412. 2019
- Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone (R) and estradiol: pharmacokinetics from a dose-finding study. 97:422-427. 2018
- A phase I randomized postcoital testing and safety study of the Caya diaphragm used with 3% Nonoxynol-9 gel, ContraGel or no gel. 96:124-130. 2017
- Assessment of the vaginal residence time of biomarkers of semen exposure. 94:512-520. 2016
- Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptive. 93:52-57. 2016
- Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone (R) and ethinyl estradiol. 93:58-64. 2016
- Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. 92:439-444. 2015
- New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study. 91:211-216. 2015
- Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill. 91:204-210. 2015
- Does tenofovir gel or do other microbicide products affect detection of biomarkers of semen exposure in vitro?. 90:136-141. 2014
- Effect of oral administration of a continuous 18 day regimen of meloxicam on ovulation: experience of a randomized controlled trial. 90:168-173. 2014
- Effect of lubricants and a vaginal spermicide gel on the detection of prostate specific antigen, a biomarker of semen exposure, using a quantitative (Abbott ARCHITECT) assay. 89:134-138. 2014
- Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm. 89:31-35. 2014
- The COX-2 inhibitor meloxicam prevents pregnancy when administered as an emergency contraceptive to nonhuman primates. 88:744-748. 2013
- A statement on abortion by 100A professors of obstetrics: 40 years later. 88:568-576. 2013
- TSPY4 is a novel sperm-specific biomarker of semen exposure in human cervicovaginal fluids; potential use in HIV prevention and contraception studies. 88:387-395. 2013
- Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics. 87:738-743. 2013
- The LIF receptor antagonist PEGLA is effectively delivered to the uterine endometrium and blocks LIF activity in cynomolgus monkeys. 87:813-823. 2013
- Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. 87:744-749. 2013
- Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrel. 87:201-211. 2013
- Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise. 87:212-219. 2013
- Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. 85:595-601. 2012
- Reddy female condom: functional performance of a 90-mm shaft length in two clinical studies. 83:466-471. 2011
- Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen. 80:245-253. 2009
- Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant. 79:469-478. 2009
- Effects of progesterone, levonorgestrel and medroxyprogesterone acetate on apoptosis in human endometrial endothelial cells. 79:139-145. 2009
- Comparative crossover study of the PATH Woman's Condom and the FC Female Condom (R). 78:465-473. 2008
- SILCS diaphragm: postcoital testing of a new single-size contraceptive device. 78:237-244. 2008
- Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in levonorgestrel subcutaneous implant users. 78:106-112. 2008
- Fourteen-day safety and acceptability study of the universal placebo gel. 75:136-141. 2007
- Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mu g (Loestrin (R) 24 Fe). 75:16-22. 2007
- Chronic endometritis in DMPA users and Chlamydia trachomatis endometritis.. 76:49-52. 2007
- Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. 74:439-445. 2006
- Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. 74:133-140. 2006
- FemCap (TM) with removal strap: ease of removal, safety and acceptability. 73:59-64. 2006
- Male tolerance of ACIDFORM gel. 71:443-446. 2005
- Safety and efficacy of Implanon (TM), a single-rod implantable contraceptive containing etonogestrel. 71:319-326. 2005
- Morbid obesity: potential effects of hormonal contraception 2018
- The importance of pharmacokinetic studies in drug development 2013
- Critical next steps for female condom research - report from a workshop 2009
- Body mass index and weight are predictors of pregnancy in a phase 3 multicenter contraceptive efficacy study of AG200-15, a low-dose combination hormonal contraceptive patch 2018
- Safety and efficacy results for the segesterone acetate ethinyl estradiol (SA/EE) contraceptive vaginal ring 2018
- EFFECTS OF MELOXICAM, A SEMI-SELECTIVE CYCLO-OXYGENASE 2 (COX-2) INHIBITOR, ON THE ULTRASOUND APPEARANCE OF THE DOMINANT FOLLICLE BEFORE AND AFTER THE LUTEINIZING HORMONE (LH) SURGE 2013
- SERUM ETHINYL ESTRADIOL LEVELS WITH A LOW-DOSE COMBINATION TRANSDERMAL CONTRACEPTIVE (AG200-15) COMPARED WITH A LOW-DOSE COMBINATION ORAL CONTRACEPTIVE 2012
- A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women 2015
- Gestodene: A review of its pharmacology, potency and tolerability in combined contraceptive preparations 2014
- Ethinyl estradiol and 17 beta-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment 2013
- Biomarkers of semen in the vagina: applications in clinical trials of contraception and prevention of sexually transmitted pathogens including HIV 2007
- Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives 2006
Identity
International Standard Serial Number (ISSN)
- 0010-7824
Electronic International Standard Serial Number (EISSN)
- 1879-0518